ALK and non-small cell lung carcinoma: Nishio et al. reported a PFS of 13.6 months and a 56% hazard reduction of disease progression and death for Asian patients in the PROFILE 1014 compared to a PFS of 9.6 months and a 48% hazard reduction for non‐Asian patients in the same study.24 Taken together, the present study demonstrated a good efficacy of ceritinib and crizotinib treatment for Asian Taiwanese patients with ALK‐positive NSCLC, with a superior efficacy in favor of ceritinib treatment.